Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02780011
Title Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors The Methodist Hospital System
Indications

skin angiosarcoma

embryonal testis carcinoma

lymphoma

Advanced Solid Tumor

nasopharynx carcinoma

Therapies

Alisertib + Brentuximab vedotin

Age Groups: adult
Covered Countries USA


No variant requirements are available.